Literature DB >> 1848284

Intracranial germ-cell tumors in children.

H J Hoffman1, H Otsubo, E B Hendrick, R P Humphreys, J M Drake, L E Becker, M Greenberg, D Jenkin.   

Abstract

All patients with confirmed intracranial germ-cell tumors treated at the Hospital of Sick Children during the period January, 1952, to December, 1989, were reviewed. Of the 51 tumors reviewed, 16 were located in the suprasellar region, 32 in the pineal region, and three in both the pineal and the suprasellar regions. Forty-nine patients underwent surgical resection which was total in seven and partial in 20, and consisted of a biopsy in 22. Two patients were managed on the basis of serum and cerebrospinal fluid markers. Surgical tools such as the operating microscope, the ultrasonic surgical aspirator, and the laser beam allowed safe debulking and removal of the deep-seated tumors in the pineal region. There were no operative deaths in the 36 patients treated since 1972, who included 23 with pineal tumors. Twenty-five patients with germinomas received radiotherapy and had a 5-year survival rate of 85.1%. Thirteen patients with non-germinoma germ-cell tumors received radiotherapy and had a 5-year survival rate of 45.5%. On the basis of this review, the authors recommend resection of pineal and suprasellar germ-cell tumors in order to firmly establish an accurate histological diagnosis to guide the extent of adjuvant therapy. In the case of a pure germinoma without evidence of dissemination, adjuvant therapy consists only of local radiotherapy. On the other hand, for malignant non-germinoma germ-cell tumors, adjuvant therapy must include chemotherapy as well as craniospinal axis radiotherapy.

Entities:  

Mesh:

Year:  1991        PMID: 1848284     DOI: 10.3171/jns.1991.74.4.0545

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  77 in total

1.  Primary intracranial germ cell tumours (GCT) fail to highlight important aspects of the current management of this condition.

Authors:  S Senan
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

2.  Treatment of malignant intracranial germ cell tumours.

Authors:  S Senan
Journal:  BMJ       Date:  1992-07-04

3.  Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.

Authors:  J Lee Villano; Irim Y Virk; Vanessa Ramirez; Jennifer M Propp; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

4.  Atypical location of intracranial germinoma: a case report.

Authors:  C Piette; C Hoyoux; O Luckers; M Tebache
Journal:  Clin Neuroradiol       Date:  2013-12-06       Impact factor: 3.649

5.  Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy.

Authors:  P L Robertson; R C DaRosso; J C Allen
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

6.  Long-term functional outcome of suprasellar germinomas: usefulness and limitations of radiotherapy.

Authors:  H Oka; N Kawano; T Tanaka; S Utsuki; I Kobayashi; H Maezawa; K Fujii
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

7.  Differences still exist in the approach to the diagnosis and management of pineal lesions.

Authors:  S Senan
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

Review 8.  The management of bifocal intracranial germinoma in children.

Authors:  R Al-Mahfoudh; R Zakaria; E Irvine; B Pizer; C L Mallucci
Journal:  Childs Nerv Syst       Date:  2013-10-03       Impact factor: 1.475

9.  CT and MRI features of intracranial germ cell tumors.

Authors:  T Fujimaki; M Matsutani; N Funada; T Kirino; K Takakura; O Nakamura; A Tamura; K Sano
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

Authors:  J Lee Villano; Jennifer M Propp; Kimberly R Porter; Andrew K Stewart; Tibor Valyi-Nagy; Xinyu Li; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.